LOW-DOSE ASPIRIN IN POLYCYTHEMIA-VERA - A PILOT-STUDY

Authors
BARBUI T DEGAETANO G FINAZZI G LANDOLFI R MARCHIOLI R PATRONO C TOGNONI G CAPANI F DECARLI A GAMBI D NENCI GG TURA S MANDELLI F ROSSIFERRINI P CORTELAZZO S VESTRI O FINELLI C NOCENTINI F POGLIANI EM MICCOLIS IR BIZZI B ROCCA B TARTAGILIONE R ANGELI G DIBLASIO A DIPASQUALE A KRAMER V MARFISI RM OLIVIERI M SCIULLI L SPOLTORE R MONTEFUSCO E SPADEA A CAROTENUTO M NOBILE M MORELLI A RESEGOTTI L VASINO MAC RODEGHIERO F RUGGERI M
Citation
T. Barbui et al., LOW-DOSE ASPIRIN IN POLYCYTHEMIA-VERA - A PILOT-STUDY, British Journal of Haematology, 97(2), 1997, pp. 453-456
Citations number
9
Categorie Soggetti
Hematology
Journal title
British Journal of Haematology → ACNP
ISSN journal
00071048
Volume
97
Issue
2
Year of publication
1997
Pages
453 - 456
Database
ISI
SICI code
0007-1048(1997)97:2<453:LAIP-A>2.0.ZU;2-S
Abstract
In this pilot study, aimed at exploring the feasibility of a large-sca le trial of low-dose aspirin in polycythaemia vera (PV), 112 PV patien ts (42 females, 70 males, aged 17-80 years) were selected for not havi ng a clear indication for, or contraindication to, aspirin treatment a nd randomized to receive oral aspirin (40 mg/d) or placebo, Follow-up duration was 16 +/- 6 months. Measurements of thromboxane A(2) product ion during whole blood clotting demonstrated complete inhibition of pl atelet cyclooxygenase activity in patients receiving aspirin. Aspirin administration was not associated with any bleeding complication. With in the limitations of the small sample size, this study indicates that a biochemically effective regimen of antiplatelet therapy is well tol erated in patients with polycythaemia vera and that a large-scale plac ebo-controlled trial is feasible.